sb 203580 has been researched along with stearoyl alpha-lysolecithin in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (stearoyl alpha-lysolecithin) | Trials (stearoyl alpha-lysolecithin) | Recent Studies (post-2010) (stearoyl alpha-lysolecithin) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 25 | 1 | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, HB; Choi, JI; Hur, YH; Kim, JM; Kim, MY; Quan, H; Xin, C | 1 |
1 other study(ies) available for sb 203580 and stearoyl alpha-lysolecithin
| Article | Year |
|---|---|
Stearoyl lysophosphatidylcholine enhances the phagocytic ability of macrophages through the AMP-activated protein kinase/p38 mitogen activated protein kinase pathway.
Topics: AMP-Activated Protein Kinases; Animals; Escherichia coli; Imidazoles; Lysophosphatidylcholines; Macrophages, Peritoneal; Male; Mice; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phagocytosis; Phosphorylation; Pyridines; RAW 264.7 Cells; RNA, Small Interfering; Signal Transduction | 2016 |